Enlightened funds no longer see tech as a luxury, but rather as mission critical to attracting investment, winning deals, extracting maximum portfolio value and delivering results.

Companies have more options than ever before to access private capital across debt, minority or majority equity investments.

For the SPAC sponsor, without the benefit of the portfolio risk management of a venture fund, the risk-reward profile for a private biotech acquisition is not for the faint of heart.